Clinical Trial Update: Evaluation of the Efficacy and Safety of AFQ056 in Reducing Moderate to Severe L-dopa Induced Dyskinesias in Patients With Parkinson's Disease [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the efficacy and safety of AFQ056 to reduce L-dopa-induced dyskinesias in Parkinson disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• L-dopa-induced Dyskinesia
• Parkinson Disease

Drugs mentioned

• AFQ056 (mavoglurant)

Snippet

Sponsor: Novartis | Conditions: Parkinson Disease, Dyskinesias | Phase 2 | Status: COMPLETED